Campath for T cell lymphomas – pro

Athough alemtuzumab is an anti-B antibody, several phase II studies suggest that it is effective for Tcell lymphoma, particularly, CTCL , and Mycosis Fungoides but also peripheral T-cell lymphoma. NCCN Mycosis Fungoides Guideline refers one to the T0cell guideline and it lists alemtuzumab with a notes that says that “activity has been demonstrated in small clinical trials and additional larger clinical trials are necessary”.

Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23.

Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23.

Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed o chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103: 2920-2924.[Abstract/Free Full Text]

Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol. 2003;71: 250-256.[CrossRef][Medline] [Order article via Infotrieve]
Articles citing this article

Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients
haematol 2007 92:784-794

nccn.org, T-cell, TCELL-B

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal

Professional